- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03025724
Photodynamic Therapy for Treatment of Cutaneous Squamous Cell Carcinoma in Situ
This pilot study will evaluate the effectiveness of using photodynamic therapy for treatment of cutaneous squamous cell in situ (SCCis). Our hypothesis is that PDT will be effective for treating SCCis. This study will also secondarily evaluate the tolerability of using photodynamic therapy for treatment of SCCis.
Investigators plan to enroll 40 subjects with biopsy proven SCCis. Exclusion criteria include lesion in high-risk site (head, neck, hands, feet), previous severe adverse reaction to topical 20% aminolevulinic acid (Kerastick), previous severe adverse reaction to blue light (BLU-U), allergy to Tegaderm, primary or secondary immunosuppression, history of > 6 skin cancers in the past year, photosensitizing condition such as lupus, or sensitivity to porphyrins.
Age, gender, size, and location of the SCCis will be recorded. All subjects will receive surgical treatment of their SCCis. The control group will undergo a surgical excision of the tumor. After the excision, subjects will be asked to fill out a satisfaction survey. The intervention group will receive PDT plus surgical treatment. Photographs of the lesion will be taken at each study visit. Subjects in the intervention group will then undergo the study procedure of application of topical 20% 5-ALA (Levulan Kerastick; DUSA Pharmaceuticals) to the SCCis. At 3-5 weeks after the initial treatment, the subject will repeat the 3-hour ALA incubation and blue light exposure. At 6 months after the last treatment, subjects in the intervention group will return for clinical follow-up and surgical excision of the lesion. After excision, the specimen will be sent for processing by pathology and subjects will be asked to fill out a satisfaction visual analog scale. All slides will be read by a board-certified dermatopathologist. Side effects will also be monitored using the same graded scale described previously. Mild adverse events that have been associated with PDT, including erythema, skin crusting, superficial blistering, hypopigmentation, and hyperpigmentation. These reactions usually occur during or immediately after the PDT treatment.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Objective: This trial will evaluate the effectiveness of photodynamic therapy (aminolevulinic acid plus blue light) for treatment of cutaneous squamous cell carcinoma in situ (SCCis).
This pilot study will prospectively recruit 40 subjects with biopsy proven SCCis at the time of their visit at University Dermatology East Providence office. Exclusion criteria include lesion in high-risk site (head, neck, hands, feet), previous severe adverse reaction to topical 20% aminolevulinic acid (Kerastick), previous severe adverse reaction to blue light (BLU-U), allergy to Tegaderm, primary or secondary immunosuppression, history of > 6 skin cancers in the past year, photosensitizing condition such as lupus, or sensitivity to porphyrins.
Half of the subjects will be randomized to the control group (n=20), and the remaining subjects (n=20) will be randomized to the intervention group. The subject's age and gender, and size and location of the SCCis will be recorded. For the control group, subjects will undergo a surgical excision of the tumor, which is the gold standard of treatment for SCCis. After the excision, subjects will be asked to fill out a satisfaction survey. They will not receive any PDT treatment.
For the intervention group, photographs of the lesion will be taken at each study visit. A clear transparency film will be used to trace the clinical margins of the lesion, as well as any other distinctive skin markings such as nevi or birthmarks. Subjects will then undergo the study procedure. The area to be treated will be swabbed with an alcohol wipe and allowed to dry. The investigator will apply topical 20% 5-ALA to the SCCis. Then, the area will be covered with Tegaderm film for 3 hours. At the end of 3 hours, the Tegaderm will be removed and the subject will be exposed to a blue light source, which is the standard protocol for treatment with blue light PDT. During administration of the light and immediately afterwards, the subject will be monitored for any side effects, such as erythema, edema, stinging/burning, blisters/crusting, hyperpigmentation, and hypopigmentation. These items will be graded on a scale of 1 to 4 (1=mild and 4=severe) assessed immediately after treatment. This process will be repeated at the next visit 3-5 weeks later. At six months after the last treatment, subjects in the intervention group will return for clinical follow-up and surgical excision of the lesion. Patients will complete a satisfaction survey at the end of this visit.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age > 18, any gender
- Biopsy proven SCCis without evidence of microinvasion beyond the epidermis
- Low-risk site (trunk, arms, legs)
- Clinical presence of tumor at biopsy site to ensure that biopsy itself was not curative
- Lesion <2cm
- Subject amenable to surgical excision at 6 months after the last PDT treatment
Exclusion Criteria:
- High-risk site (head, neck, hands, feet)
- Previous severe adverse reaction to topical 20% aminolevulinic acid (Kerastick)
- Previous severe adverse reaction to blue light (BLU-U)
- Allergy to Tegaderm
- Exclusion of any patient with primary or secondary immunosuppression
- History of > 6 skin cancers in the past year
- Photosensitizing condition such as lupus
- Sensitivity to porphyrins
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control
After the surgical excision, subjects will be asked to fill out a satisfaction survey.
They will not receive any PDT treatment.
|
|
Experimental: Intervention Group
Subjects will undergo a surgical excision of the tumor.
Then a clear transparency film will be used to trace the clinical margins of the lesion, as well as any other distinctive skin markings such as nevi or birthmarks.
Subjects will then undergo the study procedure where the area to be treated will be swabbed with an alcohol wipe and allowed to dry.
Next, the investigator will apply topical 20% 5-ALA (Levulan Kerastick; DUSA Pharmaceuticals) to the SCCis.
Then, the area will be occluded with Tegaderm film for 3 hours.
At the end of the incubation period, the Tegaderm will be removed and the patient will be exposed to a blue light source (BLU-U; DUSA Pharmaceuticals).
Lastly, they will be asked to fill out a satisfaction survey.
|
Intervention group subjects will undergo a surgical excision of the tumor.
Then a clear transparency film will be used to trace the clinical margins of the lesion, as well as any other distinctive skin markings such as nevi or birthmarks.
Subjects will then undergo the study procedure where the area to be treated will be swabbed with an alcohol wipe and allowed to dry.
Next, the investigator will apply topical 20% 5-ALA (Levulan Kerastick; DUSA Pharmaceuticals) to the SCCis.
Then, the area will be occluded with Tegaderm film for 3 hours.
Other Names:
At the end of the incubation period, the Tegaderm will be removed and the patient will be exposed to a blue light source (BLU-U; DUSA Pharmaceuticals).
Participants will be asked to fill out a satisfaction survey.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate the incidence of SCCis present after exposure to the experimental procedures
Time Frame: six months
|
After the excision, investigators will collect patient satisfaction data.
Investigators will also review the final pathology report for presence or absence of the tumor.
|
six months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Physician graded scoring on a 1 to 4 scale of erythema, edema, stinging/burning, blisters/crusting, hyperpigmentation, and hypopigmentation.
Time Frame: six months
|
The subjects will be monitored for any side effects, such as erythema, edema, stinging/burning, blisters/crusting, hyperpigmentation, and hypopigmentation.
These items will be graded on a scale of 1 to 4 (1=mild and 4=severe) assessed immediately after treatment.
|
six months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Kachiu C. Lee, MD, University Dermatology
Publications and helpful links
General Publications
- Green A. Changing patterns in incidence of non-melanoma skin cancer. Epithelial Cell Biol. 1992 Jan;1(1):47-51.
- Glass AG, Hoover RN. The emerging epidemic of melanoma and squamous cell skin cancer. JAMA. 1989 Oct 20;262(15):2097-100.
- Brancaleon L, Moseley H. Laser and non-laser light sources for photodynamic therapy. Lasers Med Sci. 2002;17(3):173-86. doi: 10.1007/s101030200027.
- Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B. 1990 Jun;6(1-2):143-8. doi: 10.1016/1011-1344(90)85083-9.
- Tierney E, Barker A, Ahdout J, Hanke CW, Moy RL, Kouba DJ. Photodynamic therapy for the treatment of cutaneous neoplasia, inflammatory disorders, and photoaging. Dermatol Surg. 2009 May;35(5):725-46. doi: 10.1111/j.1524-4725.2009.01117.x. Epub 2009 Mar 20.
- Rogers HW, Weinstock MA, Harris AR, Hinckley MR, Feldman SR, Fleischer AB, Coldiron BM. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol. 2010 Mar;146(3):283-7. doi: 10.1001/archdermatol.2010.19.
- Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol. 1994 May;30(5 Pt 1):774-8. doi: 10.1016/s0190-9622(08)81509-5.
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 897494
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Squamous Cell Carcinoma
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Bristol-Myers SquibbCompletedStage IVA Oral Cavity Squamous Cell Carcinoma | Stage IV Hypopharyngeal Squamous Cell Carcinoma | Stage IVA Laryngeal Squamous Cell Carcinoma | Stage IVA Oropharyngeal Squamous Cell Carcinoma | Stage IVB Laryngeal Squamous Cell Carcinoma | Stage IVB Oropharyngeal Squamous Cell Carcinoma | Stage... and other conditionsUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Stage IVA Oral Cavity Squamous Cell Carcinoma | Stage IVA Laryngeal Squamous Cell Carcinoma | Stage... and other conditionsCanada, United States
-
Emory UniversitySynta Pharmaceuticals Corp.TerminatedStage IVA Oral Cavity Squamous Cell Carcinoma | Stage IVA Laryngeal Squamous Cell Carcinoma | Stage IVA Oropharyngeal Squamous Cell Carcinoma | Stage I Hypopharyngeal Squamous Cell Carcinoma | Stage I Laryngeal Squamous Cell Carcinoma | Stage I Oropharyngeal Squamous Cell Carcinoma | Stage II... and other conditionsUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma | Stage IVA Oral Cavity Squamous Cell... and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedRecurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Caregiver | Salivary Gland Squamous Cell Carcinoma | Malignant Head and Neck Neoplasm | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Stage... and other conditionsUnited States
-
NRG OncologyNational Cancer Institute (NCI)RecruitingAdvanced Head and Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of Unknown Primary | Advanced Hypopharyngeal Squamous Cell Carcinoma | Advanced Laryngeal Squamous Cell Carcinoma | Advanced Oropharyngeal Squamous Cell CarcinomaUnited States, Canada
-
City of Hope Medical CenterNational Cancer Institute (NCI); Genentech, Inc.RecruitingLocally Advanced Skin Squamous Cell Carcinoma | Unresectable Skin Squamous Cell Carcinoma | Resectable Skin Squamous Cell CarcinomaUnited States
-
Baptist Health South FloridaRegeneron PharmaceuticalsWithdrawnSquamous Cell Carcinoma | Cutaneous Squamous Cell Carcinoma | Advanced Squamous Cell CarcinomaUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteAstraZeneca; Brooklyn ImmunoTherapeutics, LLCActive, not recruitingSquamous Cell Carcinoma of the Head and Neck | Oropharynx Squamous Cell Carcinoma | Squamous Cell Carcinoma | Oral Cavity Squamous Cell Carcinoma | Metastatic Squamous Cell Carcinoma | Hypopharynx Squamous Cell Carcinoma | Paranasal Sinus Squamous Cell Carcinoma | Larynx Squamous Cell CarcinomaUnited States
-
UNC Lineberger Comprehensive Cancer CenterMayo Clinic; National Institute of Dental and Craniofacial Research (NIDCR)RecruitingCarcinoma, Squamous Cell | Head and Neck Squamous Cell Carcinoma | Oropharyngeal Squamous Cell Carcinoma | Oropharynx Squamous Cell CarcinomaUnited States
Clinical Trials on Levulan Kerastick
-
University of California, DavisCompletedSeborrheic DermatitisUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)Not yet recruitingActinic KeratosesUnited States
-
DUSA Pharmaceuticals, Inc.Completed
-
Princess Al-Johara Al-Ibrahim Cancer Research CenterCompletedTransitional Cell Carcinoma of the BladderSaudi Arabia
-
Inova Health Care ServicesDUSA Pharmaceuticals, Inc.CompletedNonmelanoma Skin CancersUnited States
-
The Cleveland ClinicCompletedActinic KeratosisUnited States
-
DUSA Pharmaceuticals, Inc.Completed
-
Dermatology, Laser & Vein Specialists of the CarolinasCompleted
-
Edward Maytin, MD, PhDDUSA Pharmaceuticals, Inc.CompletedBasal Cell Nevus SyndromeUnited States
-
Medical Dermatology SpecialistsDUSA Pharmaceuticals, Inc.CompletedActinic Keratosis | Skin Cancer | Non-melanoma Skin Cancer | Sun Damaged SkinUnited States